127 0 obj
<>/Filter/FlateDecode/ID[<9350FCCC5B36A144B09E957EFF9082DD><85EDD3AB9D3D97488E8C718CB0998D0D>]/Index[103 47]/Info 102 0 R/Length 115/Prev 100422/Root 104 0 R/Size 150/Type/XRef/W[1 3 1]>>stream
Survival through 100 days was significantly greater in patients who achieved a day 28 OR (82%) compared with patients that did not achieve day 28 OR (39%), with 67% overall day 100 survival.Consistent with the findings in Study 275, Day 28 OR was achieved in 70% of children. These include REVASCOR for advanced chronic heart failure and MPC-06-ID for chronic low back pain due to degenerative disc disease, which are in phase 3 with readouts expected in the upcoming quarter.Trial data from the three phase 3 trials of RYONCIL for pediatric steroid-refractory aGVHD is summarized below. Mesoblast is also pursuing clinical trials for Ryoncil in adult and chronic GVHD and to treat acute respiratory distress syndrome in COVID-19 patients, among other indications. Similar predictive value of day 28 was also seen in survival through day 180 (79% vs. 43.8%, P= 0.003). At time of writing, total confirmed cases were approaching 114,000, while total deaths were just under 4000. They express a number of receptors for various inflammatory cytokines, including TNF-alpha receptor, IL-1 receptor, IL-6 receptor, interferon gamma receptor.” They are activated when introduced in the middle of a cytokine storm, and release anti-inflammatory mediators to regulate and control multiple arms of the immune system thereby switching off the severe inflammatory response that is responsible for the damage to tissues forming the basis of the diseases that the company is targeting.“Mesenchymal lineage cells are collected from the bone marrow of healthy adult donors and proprietary processes are utilized to expand them to a uniform, well characterized, and highly reproducible cell population. Mesoblast Limited MESO announced that the FDA has accepted the biologics license application (BLA) for its lead product candidate Ryoncil (remestemcel-L), … Available for Android and iOS devices. It is also being developed for adult steroid-refractory aGVHD and chronic GVHD. According to the company, MSCs have already proven effective against Covid-19-caused conditions.Mesoblast said in a recent clinical study which tested MSCs in seven patients with severe Covid-19 pneumonia, the treatment either completely cured or significantly improved functional outcomes for all patients.On top of this, remestemcel-L itself has previously been proven to improve lung function in patients with chronic obstructive pulmonary disease (COPD). Mesoblast’s Biologics License Application to seek approval of its product candidate RYONCIL™ (remestemcel-L) for pediatric steroid-refractory acute graft versus host disease has … I am not receiving compensation for it (other than from Seeking Alpha). endstream
endobj
104 0 obj
<>/Metadata 9 0 R/PageLayout/OneColumn/Pages 101 0 R/StructTreeRoot 25 0 R/Type/Catalog>>
endobj
105 0 obj
<>/ExtGState<>/Font<>/XObject<>>>/Rotate 0/StructParents 0/Tabs/S/Type/Page>>
endobj
106 0 obj
<>stream
Mesoblast told shareholders today it will be testing its remestemcel-L product on coronavirus patients who develop acute respiratory distress syndrome (ARDS) from the infection.According to Mesoblast, the mortality rate for Covid-19 patients with ARDS is upwards of 50 per cent. Mesoblast Ltd. (MESO:NASDAQ; MSB:ASX), which concentrates its efforts on inflammatory diseases, today announced that "the Oncologic Drugs Advisory Committee (ODAC) of the U.S. Food and Drug Administration (FDA) voted overwhelmingly in favor that the available data support the efficacy of remestemcel-L (RYONCIL™) in pediatric patients with steroid-refractory acute graft … It has sufficient runway for transitioning to a commercial organization with its own product sales.Mesoblast uses a proprietary technology platform developing mesenchymal lineage cells that are “found in every vascularized tissue around blood vessels. As in study 275, clinical response at day 28 was highly predictive of improved survival through day 100 (87% compared to 47% in patients that did not achieve day 28 OR P = 0.0001). Mesoblast completed a USD $90M capital raising in May with a significant proportion of proceeds to scale-up manufacturing of Remestemcel-L for treating COVID-19 … Now, the drug will be tested on coronavirus patients in the U.S., Australia, China, and Europe.Mesoblast announced today's news in the midst of a struggling market and helped offset some losses as it gained 22.40 per cent by midday AEDT. Mesoblast's stem cell therapy candidate has had an outstanding advisory committee meeting where it was voted 9-1.Here's a quick look at future prospects for this company which we recommended to our subscribers last year.Speaking at the 2020 Full-Year Financial Results and Corporate Highlights Webcast on 8/27/2020, CEO Dr. Silviu Itescu said the lead product candidate RYONCIL has a targeted market. The proceeds from the offering will be used for commercial launch of RYONCIL for acute GVHD, will also support a scale-up of manufacturing for... maturing pipeline, including GVHD label extensions and for COVID-19 ARDS and also support the clinical programs underlying those.” Additionally, up to $67.5 million may be available through existing strategic partnerships and ongoing financing facilities over the next 12 months.The company has an extensive portfolio of “over 1,100 patents and patent applications that cover compositions of matter, manufacturing and therapeutic applications of mesenchymal lineage cells” with protection extending through 2040 in all major markets.The company has licensing and royalty agreements with Japan based JCR Pharmaceuticals Acute GVHD occurs in approximately 50% of patients who receive an allogeneic bone marrow transplant (BMT). 149 0 obj
<>stream